Literature DB >> 26177174

Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Edda Spiekerkoetter1, Yon K Sung1, Deepti Sudheendra1, Matthew Bill1, Micheala A Aldred2, Mariëlle C van de Veerdonk3, Anton Vonk Noordegraaf3, Janel Long-Boyle4, Rajesh Dash1, Phillip C Yang1, Allan Lawrie5, Andrew J Swift5, Marlene Rabinovitch1, Roham T Zamanian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26177174      PMCID： PMC4532822          DOI： 10.1164/rccm.201411-2061LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  15 in total

Review 1.  Treatment of pulmonary arterial hypertension.

Authors:  Marc Humbert; Olivier Sitbon; Gérald Simonneau
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

2.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

3.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension.

Authors:  Gert-Jan Mauritz; Taco Kind; J Tim Marcus; Harm-Jan Bogaard; Mariëlle van de Veerdonk; Pieter E Postmus; Anco Boonstra; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  Chest       Date:  2011-09-29       Impact factor: 9.410

5.  Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Micheala A Aldred; Victoria James; Rachel E Harrison; Bhakti Patel; Edward C Schwalbe; Ekkehard Gruenig; Bart Janssen; Rolf Koehler; Werner Seeger; Oliver Eickelberg; Horst Olschewski; C Gregory Elliott; Eric Glissmeyer; John Carlquist; Miryoung Kim; Adam Torbicki; Anna Fijalkowska; Grzegorz Szewczyk; Jasmine Parma; Marc J Abramowicz; Nazzareno Galie; Hiroko Morisaki; Shingo Kyotani; Norifumi Nakanishi; Takayuki Morisaki; Marc Humbert; Gerald Simonneau; Olivier Sitbon; Florent Soubrier; Florence Coulet; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mutat       Date:  2006-02       Impact factor: 4.878

6.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.

Authors:  J R Thomson; R D Machado; M W Pauciulo; N V Morgan; M Humbert; G C Elliott; K Ward; M Yacoub; G Mikhail; P Rogers; J Newman; L Wheeler; T Higenbottam; J S Gibbs; J Egan; A Crozier; A Peacock; R Allcock; P Corris; J E Loyd; R C Trembath; W C Nichols
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

7.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

8.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

Authors:  Edda Spiekerkoetter; Xuefei Tian; Jie Cai; Rachel K Hopper; Deepti Sudheendra; Caiyun G Li; Nesrine El-Bizri; Hirofumi Sawada; Roxanna Haghighat; Roshelle Chan; Leila Haghighat; Vinicio de Jesus Perez; Lingli Wang; Sushma Reddy; Mingming Zhao; Daniel Bernstein; David E Solow-Cordero; Philip A Beachy; Thomas J Wandless; Peter Ten Dijke; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2013-07-15       Impact factor: 14.808

Review 9.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Alessandra Manes; Luca Negro; Massimiliano Palazzini; Maria Letizia Bacchi-Reggiani; Angelo Branzi
Journal:  Eur Heart J       Date:  2009-01-20       Impact factor: 29.983

10.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690
View more
  50 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

3.  Acute right ventricular failure after orthotopic liver transplantation.

Authors:  Rohan M Goswami; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2018-01

Review 4.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

5.  Catching a Disease: A Molecular Trap as a Therapy for Pulmonary Arterial Hypertension.

Authors:  Beth L Roman; Cynthia St Hilaire
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

6.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

7.  [Pulmonary hypertension : What is new in therapy?].

Authors:  N Sommer; M Hecker; K Tello; M Richter; C Liebetrau; M A Weigand; W Seeger; A Ghofrani; H Gall
Journal:  Anaesthesist       Date:  2016-08       Impact factor: 1.041

Review 8.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

9.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

10.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.